Compare Global X Autonomous & Electric Vehicles (DRIV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs TransMedics Group Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.85, while TransMedics Group Inc trades at $87 (market cap $3.10B). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| DRIV | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $42.53 | $150.42 |
52-Week Low | $25.23 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $35.92, up 0.98% on the day, with a bullish technical signal supported by moving averages and ADX indicators. The stock shows strong momentum, though the short-term RSI suggests overbought conditions. Recent news highlights global EV sales growth and China's aggressive expansion, benefiting the sector. A dividend of $0.07 is scheduled for July 2026, adding income potential.
Outlook remains positive due to sector tailwinds from rising EV adoption and fuel price pressures. Key risks include competitive threats from Chinese automakers and regulatory delays. Analysts are generally bullish, but investors should monitor valuation gaps and execution risks amid rapid industry shifts.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
